Skip to main content
SpringerLink
Log in

Schwerpunkt "Theranostik"

Natrium-Jodid-Symporter-gerichtete Theranostik

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© Vorlage für die Abbildung: created with BioRender.com

Literatur

  1. Marx K et al. Cell death induced by 131 I in a differentiated thyroid carcinoma cell line in vitro: necrosis or apoptosis? Nucl Med Commun. 2006;27(4):353-8

  2. Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur. 2012;15(2):120-3

  3. Silberstein EB. Radioiodine: the classic theranostic agent. Semin Nucl Med. 2012;42(3):164-70

  4. Park HM. 123I: almost a designer radioiodine for thyroid scanning. J Nucl Med. 2002;43(1):77-8

  5. Van Nostrand D et al. (124)I positron emission tomografy versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20(8):879-83

  6. Nagarajah J et al. Iodine Symporter Targeting with (124)I/(131)I Theranostics. J Nucl Med. 2017;58(Suppl 2):34S-38S

  7. Jentzen W et al. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49(6):1017-23

  8. Haugen BR et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133

  9. Luster M et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941-59

  10. Dietlein M et al. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4]. Nuklearmedizin. 2016;55(3):77-89

  11. Van Nostrand D. Radioiodine Imaging for Differentiated Thyroid Cancer: Not All Radioiodine Images Are Performed Equally. Thyroid. 2019;29(7):901-9

  12. Chen MK et al. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid. 2012;22(3):304-9

  13. Silberstein EB. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med. 2007;48(7):1043-46

  14. Binse I et al. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Eur J Nucl Med Mol Imaging. 2016;43:(6)1011-7

  15. Phan HT et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(5):958-65

  16. Jentzen W et al. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(5):884-95

  17. Jentzen W et al. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation. Nuklearmedizin. 2015;54(3):137-43

  18. Nagarajah J et al. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. Eur J Nucl Med Mol Imaging. 2011;38(20):1862-8

  19. Weber M et al. The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2019;63(3):235-52

  20. Keston AS et al. Storage of Radioactive Iodine in a Metastasis from Thyroid Carcinoma. Science. 1942;95(2466):362-3

  21. Sawka AM et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf). 2008;69(3):479-90

  22. Dietlein M et al. [Radioiodine therapy for benign thyroid diseases (version 5). German Guideline]. Nuklearmedizin. 2016;55(6):213-20

  23. Fard-Esfahani A et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014;35(8):808-17

  24. Schlumberger M et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663-73

  25. Mallick U et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674-85

  26. Leboulleux S et al. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. N Engl J Med. 2022;386(10):923-32

  27. Ho AL et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623-32

Download references

Author information

Authors and Affiliations

  1. Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland

    David Kersting M. Sc.

Authors
  1. David Kersting M. Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kersting, D. Natrium-Jodid-Symporter-gerichtete Theranostik. InFo Hämatol Onkol 25, 12–16 (2022). https://doi.org/10.1007/s15004-022-9014-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-022-9014-6

Search

Navigation